Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported in Q4 CY2025, but sales were flat year on year at $209.8 ...

SALT LAKE CITY, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will showcase 10 studies ...

These abstracts and posters will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, which will be held Feb. 26-28 at the Moscone West Conference Center, ...

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, ...

Highl ights Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when ...

Myriad Genetics partners with broadcaster Hannah Storm to promote breast cancer risk assessment and the importance of family health history. Myriad Genetics, Inc. has announced a collaboration with ...

Myriad Genetics, Inc. announced that its MyRisk® Hereditary Cancer Test with RiskScore® was recognized in the American Journal of Human Genetics as one of the top 10 significant advances in genomic ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 4.9% in the morning session after the company reported ...

Myriad Genetics (MYGN) surged 24% in premarket trading on Tuesday after reporting a quarterly earnings beat and outlining a 2026 revenue target of $860 million to $880 million while highlighting ...

SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a ...